Applied Clinical Trials
Safeguarding trials from CRO turnover. How to ensure commitment of qualified resources through thick and thin.
To ensure the success of any clinical trial, there are many operational components that must be fully aligned. And when contract research organizations (CROs) lack the resources to make that happen, sponsors take notice. As of 2016, the overall turnover rate at CROs hit 23% internationally. Combined with an increase in clinical trials, this turnover can impact cost, time, reputation, and expertise-and that can mean the success or failure of the study. With this in mind, it is important to ensure that your CROs hire and retain skilled workers to keep trials on time and on budget.
Selecting the best CRO partner requires asking the right questions before committing to a vendor. Preparing thought-provoking questions can enable you to fully understand the scope of the CRO’s capabilities and where gaps exist. It’s not only about the scope of services a CRO provides, but the quality and retention of the resources assigned to the project. To confirm that the CRO is committed to providing qualified resources who will stick with the project from beginning to the end, you will want to consider asking the following questions:
Consider adding language within the contract tying financial incentives to CRO resource retention. This can provide peace of mind in knowing that trials are in a secure place from beginning, middle and end.
Impact of turnover at CROs
For sponsors, high employee turnover at CROs can prolong studies and, in turn, increase project costs and
cause study delays. In addition, turnover also places a burden on internal employees who are left to carry the responsibilities when their colleagues leave. In times of high CRO turnover, don’t be surprised to see your team experience operational burnout. This ripple effect can induce stress for employees that no longer have the bandwidth to meet clinical timelines or bring pharmaceutical products to market. The overall quality and continuity of the project is not only at stake-the knowledge loss that stems from losing seasoned talent can also be detrimental.
Reasons for high CRO turnover may be excessive burnout from unrealistic workload, and/or below market compensation. Whether CRO employees leave because salary compensation isn’t meeting talent expectations or operational efficiencies and workload are not in line, you’re bound to experience major repercussions.
If your studies are not meeting expectations, rethink how you approach clinical trials with a functional service provider (FSP). As opposed to using a traditional CRO approach, an FSP model is attractive, as it brings resources with more experience, offers significantly higher retention rates, and the sponsor can play an active role in selecting the resources for their team-a frequent criticism of the CRO model. The FSP model offers greater consistency, flexibility, and scalability to reduce management burden, allowing sponsors to focus on
study strategy.
Significant changes are on the horizon that are forever altering the future of the life sciences industry, not the least of which is the central role that R&D partners play in the success of development programs. Most life sciences companies are plagued by numerous outsourcing challenges that threaten the success of the organization and ultimately affect their ability to bring much-needed medicines to the patient population. Take a moment to reevaluate which solution aligns with your strategy and how it can safeguard your clinical trials and business relationships and-ultimately-deliver medical treatments to the patients in need.
John Ebeid is Vice President, Outsourcing and Operations, Randstad Life Sciences
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.